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Introduction {#sec001}
============

A proposal written by the 2010 International League Against Epilepsy (ILAE) recommends changing the term "idiopathic" to "genetic" when describing epilepsy syndromes \[[@pone.0199321.ref001]\]. Idiopathic/genetic generalized epilepsy (IGE/CGE) is classically categorized into several commonly recognizable sub-syndromes. Juvenile myoclonic epilepsy (JME), childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), and epilepsy with generalized tonic-clonic seizures alone (EGTCS) are the most common GGE subtypes \[[@pone.0199321.ref002], [@pone.0199321.ref003]\]. Of the common GGE sub-syndromes, JME, JAE, and EGTCS (but not CAE) are lifelong diseases with overlapping clinical features.

As demonstrated in family and twin studies, genetic factors are major contributors to common GGE syndromes, with heritability estimates as high as 80% in monozygotic twins \[[@pone.0199321.ref004]--[@pone.0199321.ref006]\]. Two different heritability models have been used to explain the genetic basis of common GGE syndromes, including Mendelian inheritance of a few major genes or simultaneous involvement of multiple genes with minor effects inherited in a non-Mendelian fashion \[[@pone.0199321.ref007]\]. Several GGE causative or susceptibility genes have been identified using linkage analyses of Mendelian GGE inheritance patterns and dozens of susceptibility alleles that have been reported following association analyses of non-Mendelian GGE inheritance patterns \[[@pone.0199321.ref007]--[@pone.0199321.ref009]\]. Despite the many findings associated with genetic studies of common GGE syndromes, a comprehensive understanding of these findings is limited by high genetic complexity and heterogeneity \[[@pone.0199321.ref002], [@pone.0199321.ref010]\]. A multi-gene panel testing with next-generation sequencing is more useful for analyzing diseases with high genetic heterogeneity than broader approaches such as whole exome sequencing and whole genome sequencing. Focusing on important genes or regions facilitates detailed sequencing, thus enabling rare variants to be identified \[[@pone.0199321.ref011]\].

Literature reviews support the present study design, which includes an epilepsy multi-gene panel testing for potential candidate or susceptibility genes. The study aimed to investigate associations between these genes and common GGE syndromes, including JME, JAE, and EGTCS. Furthermore, we focused on identifying causative and susceptibility genes with causative and susceptibility variants or genes using a customized multi-gene panel testing.

Materials and methods {#sec002}
=====================

Participant inclusion and exclusion criteria {#sec003}
--------------------------------------------

A cross-sectional retrospective chart review was conducted for all patients with epilepsy who were clinically diagnosed with a common GGE syndrome (JAE, JME, or EGTCS). All patients were monitored and followed up at Samsung Medical Center or Eulji General Hospital from 1990 to 2015. The diagnosis of epilepsy was made by pediatric neurologists. Epilepsy syndromes were strictly diagnosed based on the clinical and electroencephalography features proposed by the ILAE \[[@pone.0199321.ref003]\]. There was no age limit for study enrollment. Patients with a history of major psychiatric disorders (autism spectrum disorder, schizophrenia, affective disorders, or recurrent episodes requiring pharmacotherapy or treatment in a hospital) or intellectual disability were excluded.

Ethics statement {#sec004}
----------------

Ethical approval for this retrospective study was provided by the institutional review board of Samsung Medical Center (2014-07-001-004) and the ethical committee of Nowon Eulji Medical Center (2014-06-015-001). Written informed consent for genetic testing was obtained from all participants before the study began. Written informed consent was obtained from the parents for child participants; the child\'s assent was also obtained.

Control group {#sec005}
-------------

The Korean Reference Genome Database (KRGDB) houses a publicly available population web browser containing Ansan-Ansung cohort data from the Korean Genome and Epidemiology Study. In the present study, control group were from public genetic databases of 1100 Korean individuals from the Ansan-Ansung cohorts. The whole genome of 1100 Korean individuals were sequenced using an Illumina Hiseq2000 sequencer. The raw sequences were mapped to reference genome hg19 from the University of California Santa Cruz (original GRCh37 from the National Center for Biotechnology Information, Feb. 2009) via the Burrows-Wheeler alignment tool, and the mapped sequences were analyzed using sequence alignment map (SAM) tools. To ensure sequencing accuracy, the average sequencing coverage depth was at least 30X per sample.

Epilepsy multi-gene panel testing design {#sec006}
----------------------------------------

A literature review yielded 111 genes, including 50 potential candidate genes for common GGE syndromes and 61 causative genes for other genetic epilepsies with absence, myoclonic, and generalized tonic-clonic seizures.

The 50 potential genes included 6 candidate Mendelian GGE genes, such as *CACNB4*, *CASR*, *GABRA1*, *GABRD*, *CLCN2*, and *EFHC1*; 9 candidate genes based on rare copy-number variants, including *CHRNA7(15q13*.*3)*, *CYFIP1(15q11*.*2)*, *NDE1(16p13*.*11)*, *GJA8(1q21*.*1)*, *CYTSB(17p11*.*2)*, *CHRM3(1q43)*, *PLCB1(20p12*.*3)*, *NRXN1(2p16*.*3)*, and *EPM2A(6q24*.*6)*; and 35 susceptibility genes from association studies (*BRD2*, *CX36*, *ME2*, *VRK2*, *ZEB2*, *SCN1A*, *PNPO*, *KCNJ10*, *CPA6*, *TAP-1*, *SCN1B*, *EFHC2*, *JRK/JH8*, *GRM4*, *CHRNA4*, *CHRNA2*, *CHRNB2*, *SCN2A*, *KCNQ3*, *HCN1*, *CHD2*, *GABRB3*, *GABRG2*, *CACNA1A*, *LGI4*, *SLC2A1/GLUT1*, *GPHN*, *CACNA1G*, *CACNA1H*, *CACNA2D2*, *GRIK1*, *KCNMA1*, *OPRM1*, *GRIN2A*, and *CHRNB3*). Detailed features of the 111 genes are described in [S1 Table](#pone.0199321.s001){ref-type="supplementary-material"}. The size of this region was 344.061 kbp, and the number of probes totaled 6,831, with a size of 474.708 kbp. This panel of genes includes coding exon regions as well as exon--intron boundaries of the region extensions, with 10 bases from the 3′ end and 10 bases from the 5′ end.

Epilepsy multi-gene panel testing and data generation {#sec007}
-----------------------------------------------------

Genomic DNA was extracted from peripheral blood leukocytes. The Agilent SureSelect Target Enrichment protocol from the Illumina paired-end sequencing library (v. 2.0.1, May 2010), with 1 μg input DNA, was used to generate a standard exome capture library. Sequencing was performed using the HiSeq™ 2000 platform (Illumina, San Diego, USA) at Macrogen (Seoul, Republic of Korea). The quality of the whole genome sequencing reads from all samples was assessed using FastQC, and a raw data quality control process was initiated with Trimmomatic. Alignment of the sequence reads, indexing of the reference genome hg19 from the University of California Santa Cruz (original GRCh37 from the National Center for Biotechnology Information, Feb. 2009), and variant calling with a pipeline were performed using the Genome Analysis Tool Kit best practice guidelines. Alignment was performed with the Burrows-Wheeler alignment tool (version 0.7.12) and duplicate reads were marked with Picard (version 1.130, <http://broadinstitute.github.io/picard/>). Local alignment, base quality recalibration, and variant calling were performed using the Genome Analysis Tool Kit (version 3.4.0), and annotation was conducted with SnpEff (version 4.1 g) at the Bioinformatics Institute of Macrogen. Low-quality variants were manually filtered. Variants with an allele depth \< 10 were excluded, and multi-alleles at the same chromosomal position were removed. The alternate read ratio was calculated as alternative allele depth/total depth. Therefore, a boundary of allele ratios between 0.4 and 0.6 was established, within which single-nucleotide polymorphisms (SNPs) would be considered heterozygous for alternate reads. Allele ratios of 1 were considered homozygous for alternate reads.

Identification of candidate or susceptibility genes or variants from sequence data {#sec008}
----------------------------------------------------------------------------------

### Identification of pathogenic variants {#sec009}

Disease-associated single rare variants with pathogenic effects were identified according to the American College of Medical Genetics and Genomics (ACMG) guidelines \[[@pone.0199321.ref012]\]. In the present study, rare variants were defined as those with minor allele frequencies (MAFs) ≤ 0.05. Rare variants were selected according to the population frequency recorded in public databases, including 1000Gp3 (1000 Genomes Project Phase 3) and ExAC (Exome Aggregation Consortium). Considering differences in allele frequencies between ethnic groups, allele frequencies were also determined via the KRGDB. To assess the variants found in patients with disease and pathogenicity, we evaluated the ClinVar and Human Gene Mutation Database (HGMD) professional version 2017. For each single rare variant, we compared differences in the frequency between the patient and control group, using Fisher\'s exact test. A *p* value \< 0.05 was considered significant. To predict whether an amino acid substitution in a protein affects protein function, missense variants were annotated using the following protein function prediction tools: SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, LRT, MutationTaster, MutationAssessor, FATHMM, PROVEA, MetaSVM, and MetaLR. Four nucleotide conservation prediction tools including PhastCons, GERP, PhyloP, and SiPhy contributed to the predictions.

### Identification of susceptibility variants using case control association analyses {#sec010}

Non-Mendelian genetics are commonly used to explain GGE syndromes, wherein multiple susceptibility alleles exert small effects on the occurrence of disease. To determine susceptibility alleles, case control genetic association analyses were performed. We selected all coding single-nucleotide variants (SNVs). The allele frequency of coding SNVs was compared between the disease group and 1100 control group from KRGDB. The *p* values were calculated using Fisher\'s exact tests for SNVs and control group. The obtained *p* values for each SNV were then summarized via Manhattan plots. The y-axis of a Manhattan plot typically represents the negative log (base 10) of the *p* values obtained for the association tests applied. The x-axis is typically organized by chromosome (chromosome 1 to 22, X). Each dot on the Manhattan plot signifies the mean for each SNV. We identified SNVs with *p* cut-off values of 0.05 (-log~10~*p* = 1.3) and corrected *p*-values using several variants.

### Family analyses in familial cases {#sec011}

Genes with rare variations that segregate in association with Mendelian common GGE syndromes were identified for each familial case via family analyses. All affected family member samples underwent multi-gene panel testing. Rare variant candidates were selected using ACMG guidelines. Sanger confirmations were conducted for identified variants in families.

Results {#sec012}
=======

Clinical description {#sec013}
--------------------

A total of 57 patients with common IGE/GGE syndromes were enrolled in the present study, including 51 patients with sporadic disease and 6 with familial disease. Age at onset of seizures ranged from 5--34 years. [Table 1](#pone.0199321.t001){ref-type="table"} presents clinical data for the 57 patients. The pedigrees of the 6 familial groups are presented in [Fig 1](#pone.0199321.g001){ref-type="fig"}. Additionally, 8 affected family members from the 6 familial groups were included in the analyses. Thus, epilepsy multi-gene panel testing was performed for a total of 65 patients.

![Pedigree of familial cases including 6 families and 14 patients.\
Black arrows indicate probands. Darkened symbols represent affected members. Stars indicate participants in the multi-gene panel testing. Vertical arrows indicate variant sites in the sequencing chromatograms. Sanger sequencing confirmed the *CACNA1H* heterozygous variant c.2363G\>A, p.(Arg788His) in 2 patients (I-2 and II-1) from Family A. JME, juvenile myoclonic epilepsy; EGTCS, epilepsy with generalized tonic-clonic seizures.](pone.0199321.g001){#pone.0199321.g001}

10.1371/journal.pone.0199321.t001

###### Clinical data from 57 patients.

![](pone.0199321.t001){#pone.0199321.t001g}

  Trait                                     Results                               
  ----------------------------------------- ------------------------------------- ---------------
  Patients                                  57                                    
  Sex (M: F)                                1.3:1 (32:25)                         
  Average age at inclusion ± SD (years)     18.7 ± 2.0 (range, 14--23)            
  Average age at onset ± SD (years)         13.4 ± 2.7 (range, 5.2--18.4)         
  History of febrile seizure                7 (12.3%)                             
  History of previous other type epilepsy   3 (5.3%)                              
  Sporadic: Familial                        51:6                                  
  Common IGE/GGEs sub-syndrome              JME                                   45 (79.0%)
  JAE                                       7 (12.3%)                             
  EGTCS                                     5 (8.8%)                              
  EEG findings                              bilateral (poly)spike and slow wave   47/57 (82.5%)
  single focal spike/sharp wave             31/57 (54.4%)                         
  intermittent slow activity                15/57 (26.3%)                         
  photoparoxysmal response                  5/57 (8.8%)                           

M: male; F: female; IGE: idiopathic generalized epilepsy; GGE: generalized genetic epilepsy; JME: juvenile myoclonic epilepsy; JAE: juvenile absence epilepsy; EGTCS: epilepsy with generalized tonic-clonic seizures alone; EEG: electroencephalography.

Statistical results from sequence data {#sec014}
--------------------------------------

An average of 13 million reads per patient were generated. Each read was approximately 101 bp long; the average total targeted region size was 340,412 bp. Approximately 99.8% of the mapped reads included the targeted regions. The mean depth was 1342 X. [Table 2](#pone.0199321.t002){ref-type="table"} and [Fig 2](#pone.0199321.g002){ref-type="fig"} summarize the statistical results of the sequence data and quality controls.

![Cumulative depth distribution in target regions for each sample from 65 patients.\
The x-axis denotes sequencing depth, and the y-axis indicates the fraction of bases at or above a given sequencing depth. More than 97.5% of target regions were covered by more than 50 reads (A). The mean coverage depth is shown as a mean of 1342, 2 standard deviations of 682, and a range from 825 to 2649 (B). The total number of single nucleotide polymorphisms (SNPs), coding SNPs, and indels are shown (C).](pone.0199321.g002){#pone.0199321.g002}
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###### Summary of the statistics of multi-gene panel testing in the 65 studied patients.

![](pone.0199321.t002){#pone.0199321.t002g}

  Statistics                                       Results
  ------------------------------------------------ -------------------------
  Average total number of reads                    13,239,759
  Average read length (bp)                         101
  Average total yield (Mbp)                        1,337
  Average target regions (bp)                      340,412
  Average throughput depth of target regions (X)   3931,6
  Average initial mappable reads                   13.224.255
  Average % initial mappable reads                 99.8%
  On-target reads                                  6,134,209
  Average % on-target reads                        54%
  Average of mean depth of target regions (X)      1342.0
  Average % of coverage (more than 10X)            99.4%
  Average of total number of SNPs                  500.6 (range, 429--554)
  Average of transition/ transversion              2.4
  Average Het/Hom Ratio                            1.22
  Average number of % found in dbSNP142            96%
  Average of total number of missense variant      42.0 (range, 26--52)
  Average of total number of Indels                90 (range, 60--103)

bp: base pair; Mbp: mega base pairs; SNP: single nucleotide polymorphism; Indels: small insertional-deletional variations.

Identification of pathogenic variants {#sec015}
-------------------------------------

There were 3 variants that were classified pathogenic, including *GPR98* p.(Arg3227\*), *CPA6* p.(Trp19Glyfs\*4), and *CACNA1A* p.(Ile239Phefs\*5). There were 19 variants that were classified likely pathogenic, including *CHRNB3* p.(\*459Ileext\*4), *GABRD* p.(Ser230Ala), *SZT2* p.(Ala1325Ser), *SZT2* p.(Leu3266Pro), *DOCK7* p.(Val1216Ala), *SCN1A* p.(Ala1440Gly), *GRM4* p.(Asn454Tyr), *GRM4* p.(Pro30Ser), *GATM* p.(Asp264Asn), *POLG* p.(Thr251Ser), *CACNA1H* p.(Gly59Cys), *CACNA1H* p.(Pro2196Thr), *CACNA1H* p.(Lys2335Arg), *CACNA1H* p.Arg788His, *NDE1* p.(Glu153Lys), *CACNA1G* p.(Ala2166Thr), *CACNA1A* p.(Glu735Ala), *LGI4* p.(Arg375Trp), and *ARX* p.(Ala283Thr). The 22 pathogenic and likely pathogenic variants were sporadically observed in 28% (16/57) of patients. Of these pathogenic and likely pathogenic variants, the most frequently identified genes were *CACNA1H* and voltage-gated Ca^2+^ channel genes including *CACNA1A*, *CACNA1G*, and *CACNA1H*, which were observed in 32% (7/22) of patients. The three pathogenic and 19 likely pathogenic variants are summarized in [S2 Table](#pone.0199321.s002){ref-type="supplementary-material"}. We classified 109 variants with uncertain significance and 17 likely benign variants from the 148 variants identified. Characteristics of those 109 variants with uncertain significance are summarized in [S3 Table](#pone.0199321.s003){ref-type="supplementary-material"}. Additionally, 96.5% (55/57) of patients had \>1 variant that was classified as pathogenic, likely pathogenic, or of unknown significance. An average of 2.8 (range 0--7) variants other than likely benign variants were identified in each patient. Variant distributions by patient are summarized in [Table 3](#pone.0199321.t003){ref-type="table"}.

10.1371/journal.pone.0199321.t003

###### Distribution of the 131 rare variants in the 57 patients.

![](pone.0199321.t003){#pone.0199321.t003g}

  N    Pt ID     Phenotype         N of variants (P:LP:US)   1                        2                        3                        4                       5                       6                       7
  ---- --------- ----------------- ------------------------- ------------------------ ------------------------ ------------------------ ----------------------- ----------------------- ----------------------- -----------------------
  1    E-006     JME               4 (0:2:2)                 *LGI4*p.Arg375Tr         *SZT2* p.Leu3266Pro      *PCDH19* p.Asn1134His    *UBE3A* p.Arg279Gln                                                     
  2    E-007     JME               3 (0:0:3)                 *JRK* p.Gln434Arg        *NRXN1* p.Thr1394Ser     *CHRNA4* p.Thr614Met                                                                             
  3    E-011     JME               7 (0:1:6)                 *ARX* p.Ala283Thr        *CACNA1H* p.His1827Tyr   *CHRNA2* p.Ser358Ile     *GPR98* p.Ser5480Asn    *KCNQ3* p.Val640Met     *SCN9A* p.Arg1893His    *SLC25A22* p.Asp51Asn
  4    E-015     JME c PPR, FS     1 (0:0:1)                 *SCN3A* p.Arg534Ser                                                                                                                                
  5    E-017     JME               4 (0:0:4)                 *CACNA1H* p.Ala1594Ser   *CACNA1H* p.Ala1594Val   *GPR98* p.Gln4839Glu     *JRK* p.Val521Met                                                       
  6    E-021     JME, FS           3 (0:1:2)                 *SCN1A* p.Ala1440Gly     *GPR98* p.Gln4839Glu     *SZT2* p.Arg1156His                                                                              
  7    E-023     JME               7 (0:3:4)                 *CACNA1A* p.Glu735Ala    *CACNA1H* p.Pro2196Thr   *NDE1* p.Glu153Lys       *SCN3A* p.Arg534Ser     *CHRNA4* p.Arg487Trp    *GPR98* p.Gln4839Glu    *LGI1* p.Arg407His
  8    E-026-P   JME, familial     3 (0:0:3)                 *CHRNA7* p.Ala153Thr     *EPM2A* p.Ala46Pro       *SCN9A* p.Met787Val                                                                              
  9    E-027     JME, FS           7 (0:1:6)                 *SZT2* p.Ala1325Ser      *EPM2A* p.Ala46Pro       *GPR98* p.Asn6201His     *GRIN2A* p.Val187Ile    *KCNMA1* p.Glu134Gln    *MFSD8* p.Pro69Leu      *OPRM1* p.Arg390Cys
  10   E-030     JME, FS           3 (1:0:2)                 *GPR98* p.Arg3227\*      *EPM2A* p.Ala46Pro       *ZEB2* p.Glu668Asp                                                                               
  1    E-031     JME               4 (0:0:4)                 *CHD2* p.Val1346Leu      *CHRNB3* p.Val44Phe      *FOLR1* p.Arg98Trp       *SCN9A* p.Met787Val                                                     
  12   E-036     JME, FS           4 (0:0:4)                 *CACNA2D* p.Lys706Glu    *CHRNA2* p.Arg382Trp     *LIAS* p.His264Tyr       *SCN8A* p.Tyr292Cys                                                     
  13   E-040     JME               5 (0:1:4)                 *GABRD* p.Ser230Ala      *EFHC2* p.Arg486His      *EPM2A* p.Ala46Pro       *KCNMA1* p.Glu134Gln    *PNKP* p.Ala19Val                               
  14   E-041     JME               3 (0:0:3)                 *GJA8* p.Gly119Glu       *LIAS* p.Ala135Thr       *SPECC1* p.Lys234Arg                                                                             
  15   E-042     JME               1 (0:0:1)                 *SCN9A* p.Met787Val                                                                                                                                
  16   E-047-P   JME, familial     2 (1:0:1)                 *CACNA1A* p.Leu238fs     *JRK* p.Ser388Leu                                                                                                         
  17   E-052     JME               1 (0:0:1)                 *PCDH19* p.Asn1134His                                                                                                                              
  18   E-054     JME c PPR         3 (0:0:3)                 *EPM2A* p.Ala46Pro       *SCN1B* p.Cys262Tyr      *SPTAN1* p.Lys2005Arg                                                                            
  19   E-055     JME, FS           3 (0:0:3)                 *CACNA1A* p.Arg1060Cys   *GRM4* p.Arg351His       *LGI4* p.Arg256Cys                                                                               
  20   E-061     JME               0 (0:0:0)                                                                                                                                                                    
  21   E-062     JME               3 (0:0:3)                 *ALDH7A1* p.Ile21Met     *CHD2* p.Lys1491Arg      *OPRM1* p.Val386Ile                                                                              
  22   E-067     JME               4 (1:1:2)                 *CPA6* p.Cys18fs         *CACNA1H* p.Lys2335Arg   *CACNA1G* p.Gly674Arg    *GPR98* p.Ile4666Val                                                    
  23   E-068     JME               2 (0:1:1)                 *GRM4* p.Asn454Tyr       *NDE1* p.Thr202Ala                                                                                                        
  24   E-069     JME               3 (0:0:3)                 *EPM2A* p.Ala46Pro       *PRRT2* p.Lys207Asn      *TBC1D24* p.Cys8Arg                                                                              
  25   E-070     JME c PPR         2 (0:0:2)                 *GPR98* p.Gly5678Ala     *PRICKLE1* p.Ala541Ser                                                                                                    
  26   E-073     JME c PPR         1 (0:0:1)                 *SCN3A* p.Arg534Ser                                                                                                                                
  27   E-074     JME               4 (0:0:4)                 *CASR* p.Asn602Ser       *OPRM1* p.Arg390Cys      *PRICKLE1* p.Gly732Arg   *SCN3A* p.Lys1948Thr                                                    
  28   E-080     JME               6 (0:1:5)                 *GATM* p.Asp264Asn       *CASR* p.Glu952Lys       *ME2* p.Ile478Val        *NRXN1* p.Ile1175Val    *PCDH19* p.Arg1107His   *PCDH19* p.Asn1134His   
  29   E-083     JME               3 (0:0:3)                 *CACNB4* p.Arg29Gln      *EFHC2* p.Ile470Val      *NRXN1* p.Val1254Ile                                                                             
  30   E-084     JME               0 (0:0:0)                                                                                                                                                                    
  31   E-085     JME               2 (0:0:2)                 *CLCN2* p.Gly569Ser      *UBE3A* p.Ala201Thr                                                                                                       
  32   E-086     JME               1 (0:0:1)                 *TPP1* p.Arg350Gln                                                                                                                                 
  33   E-087-P   JME, familial     1 (0:0:1)                 *GPR98* p.Gly4447Asp                                                                                                                               
  34   E-090     JME c PPR         1 (0:0:1)                 *SCN2A* p.Phe328Val                                                                                                                                
  35   E-093     JME               5 (0:2:3)                 *CACNA1G* p.Ala2166Thr   *GRM4* p.Pro30Ser        *EPM2A* p.Ala46Pro       *KCNMA1* p.Glu134Gln    *PNKP* p.Glu337Gln                              
  36   E-094     JME               4 (0:0:4)                 *ALDH7A1* p.His339Arg    *CACNA1G* p.Ala1099Thr   *CACNA1G* p.Arg1243Gln   *NRXN1* p.Leu204Gln                                                     
  37   E-113     JME               3 (0:0:3)                 *EFHC1* p.Thr508Arg      *JRK* p.Ala362Thr        *SCN1B* p.Thr189Met                                                                              
  38   E-118     JME               3 (0:0:3)                 *PCDH19* p.Asn1134His    *PRICKLE1* p.Pro38Leu    *STXBP1* p.Ile427Met                                                                             
  39   E-128     JME               3 (0:0:3)                 *CHRNB3* p.Val44Phe      *EPM2A* p.Ala46Pro       *GPR98* p.Ser1568Asn                                                                             
  40   E-137     JME               1 (0:0:1)                 *CACNA1A* p.Ala1083Asp   40                       E-137                                                                                            
  41   E-138     JME               2 (0:0:2)                 *CACNA1A* p.Asn390Asp    *CHRNB2* p.Gln397Pro                                                                                                      
  42   E-167     JME               6 (0:1:5:0)               *CACNA1H* p.Gly59Cys     *EFHC2* p.Arg132Trp      *EPM2A* p.Ala46Pro       *GABRB3* p.Leu6Pro      *ME2* p.Ile478Val       *SCN3A* p.Asp1803Asn    
  43   E-173     JME               1 (0:0:1:0)               *SCN9A* p.Ser606Arg                                                                                                                                
  44   E-184-P   JME, familial     2 (0:0:2)                 *ALDH7A1* p.His339Arg    *ME2* p.Ile478Val                                                                                                         
  45   LJY       JME, familial     0 (0:0:0)                                                                                                                                                                    
  46   E-014     JAE               4 (0:0:4)                 *TBC1D24* p.Val201Met    *CACNA1A* p.Arg1060Cys   *GPR98* p.Glu777Ala      *SPECC1* p.Gly18Ser                                                     
  47   E-139     JAE               2 (0:0:2)                 *GPR98* p.Ala5513Thr     *SCN1A* p.Arg1575Cys                                                                                                      
  48   E-179     JAE               3 (0:0:3)                 *CHRNA7* p.Ala153Thr     *EPM2A* p.Ala46Pro       *GPR98* p.Ile2187Val                                                                             
  49   E-186     JAE               4 (0:1:3)                 *CHRNB3* p.Ter459fs      *CHD2* p.Asn1625Ser      *NRXN1* p.Arg697Gln      *SPTAN1* p.Asn1034Ser                                                   
  50   E-131     JAE c CAE         3 (0:0:3)                 *GRIK1* p.Arg862Gln      *PCDH19* p.Arg1107His    *PCDH19* p.Asn1134His                                                                            
  51   E-163     JAE c CAE         5 (0:2:3)                 *POLG* p.Thr251Ser       *DOCK7* p.Val1216Ala     *GPR98* p.Tyr4235Cys     *GPR98* p.Glu5098Ala    *LIAS* p.Ala135Thr                              
  52   E-185     JAE c CAE         1 (0:0:1)                 *EPM2A* p.Ala46Pro                                                                                                                                 
  53   SMJ       EGTCS, familial   3 (0:0:3)                 *CACNA1H* p.Arg788His    *KCNQ2* p.Tyr755Cys      *ME2* p.Ile478Val                                                                                
  54   E-022     EGTCS, FS         3 (0:0:3:0)               *GABRG* p.Ser8Arg        *GPR98* p.Ile1924Thr     *SCN9A* p.Met787Val                                                                              
  55   E-028     EGTCS             3 (0:0:3)                 *GABRD* p.Thr401Met      *GRM4* p.Pro854Thr       *TBC1D24* p.Cys8Arg                                                                              
  56   E-046     EGTCS             2 (0:0:2)                 *CNTNAP* p.Lys540Asn     *PNKP* p.Arg224Cys                                                                                                        
  57   E-112     EGTCS             1 (0:0:1)                 *CLCN2* p.Glu664Val                                                                                                                                

N: number; Pt ID: Patient Identification; LP: likely pathogenic; P: pathogenic; US: uncertain significance; JME: juvenile myoclonic epilepsy; JAE: juvenile absence epilepsy; EGTCS: epilepsy with generalized tonic-clonic seizures alone; CAE: childhood absence epilepsy; PPR: photoparoxysmal response; FS: febrile seizures.

Identification of susceptibility variants using case-control association analyses {#sec016}
---------------------------------------------------------------------------------

In total, 231 variants that were predicted to disrupt protein coding sequencing in 57 patients. The *p* values and -log~10~ (*p*) values are plotted against the chromosomal location of each gene (hg19) in [Fig 3](#pone.0199321.g003){ref-type="fig"}. SNVs with cut-off values of *p* ≤ 0.05 (-log~10~*p* = 1.3) were identified and adjusted to a corrected *p* value of 0.0002 (0.05/231, -log~10~*p* = 3.7). Comparisons of the 57 patients with the 1100 control participants revealed 55 variants that were significantly associated, with a *p* value of 0.05 (-log~10~*p* = 1.3). One variant, *KCNMA1* c.400G\>C, was significantly associated, with a *p* value of 0.002 (-log~10~*p* = 3.7).

![Identification of susceptibility variants using case-control analysis.\
Fisher\'s exact test *p* values calculated for 231 variants in 57 patients and 1100 participants in control group were included. Variants with statically significant *p* values ≤ 0.05 (-log~10~*p* = 1.3) and corrected *p* values of 0.0002 (-log~10~*p* = 3.7) were identified. Manhattan plots showing *p* values from the 57 patients and control groups of 1100 participants are shown. The plot shows--log~10~ *p* values (y axis) for each of the 231 single nucleotide polymorphisms against the chromosomal location (x axis). The red horizontal line indicates the significance threshold for a corrected *p* value of 0.0002, and the green horizontal line indicates a threshold for the 0.05 *p* value. SNVs = single nucleotide variations.](pone.0199321.g003){#pone.0199321.g003}

Family analyses in 6 familial cases {#sec017}
-----------------------------------

### Family A {#sec018}

An 18-year-old woman (ID: SMJ) was first assessed at 13 years of age for unprovoked GTCSs upon waking. The pedigree is illustrated in [Fig 1](#pone.0199321.g001){ref-type="fig"}. Her mother first experienced seizures at 25 years of age and received antiepileptic treatment with lamotrigine. Neither the proband nor her mother experienced any febrile generalized seizures. Morning myoclonic and absence seizures were not reported in either subject. The common GGE subtype diagnosis was EGTCS. Considering the autosomal dominant inheritance pattern and filtered heterozygous variants, the missense variant c.2363G\>A (rs532296550) p.(Arg788His) in *CACNA1H* was strongly supported as the disease-causing variant, on the basis of the reference sequence NM_021098.2. Characteristics of the *CACNA1H* p.(Arg788His) variant are summarized in [S2 Table](#pone.0199321.s002){ref-type="supplementary-material"} and [Table 4](#pone.0199321.t004){ref-type="table"}. The proband also had a heterozygous variant, c.2362C\>T p.(Arg788Cys) in *CACNA1H*, which is known as a functional polymorphism that alters T-type calcium channels. The results of Sanger sequencing are presented in [Fig 1](#pone.0199321.g001){ref-type="fig"} \[[@pone.0199321.ref013]\].

10.1371/journal.pone.0199321.t004

###### Summary of the candidate variants in the 6 familial cases.

![](pone.0199321.t004){#pone.0199321.t004g}

  Family (proband)   Phenotype         Inheritance   Gene            Isoform              Nucleotide               Amino acid                                                                                                                                                               Zygosity   ACMG classification      Reference
  ------------------ ----------------- ------------- --------------- -------------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------- ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A (SMJ)            EGTCS             AD            *CACNA1H*       *NM_021098*.*2*      c.2363G\>A               p.(Arg788His)                                                                                                                                                            Het        Likely pathogenic        Confirmed by Sanger sequencing shown in [Fig 1](#pone.0199321.g001){ref-type="fig"}. No. 14 variant in [S2 Table](#pone.0199321.s002){ref-type="supplementary-material"}.
  B (LJY)            JME               AD            No candidates                                                                                                                                                                                                                                                              
  C (E-026-P)        JME               AD            No candidates                                                                                                                                                                                                                                                              
  D (E-047-P)        JME               AR            *CACNA1A*       *NM_001127221*.*1*   c.714delT                p.(Ile239Phefs\*5)                                                                                                                                                       Het        Pathogenic               Sibling (E-047-S1) is negative. No. 19 variant in [S2 Table](#pone.0199321.s002){ref-type="supplementary-material"}.
  *JRK*              *NM_003724*.*3*   c.1163C\>T    p.(Ser388Leu)   Het                  Uncertain significance   Sibling (E-047-S1) had also heterozygous variant. Confirmed by Sanger sequencing. No. 57 variant in [S3 Table](#pone.0199321.s003){ref-type="supplementary-material"}.                                       
  E (E-087-P)        JME               AR            *GPR98*         *NM_032119*.*3*      c.13340G\>A              p.(Gly4447Asp)                                                                                                                                                           Het        Uncertain significance   Sibling (E-087-S1) had also heterozygous variant. Confirmed by Sanger sequencing. No. 33 variant in [S3 Table](#pone.0199321.s003){ref-type="supplementary-material"}.
  F (E-184-P)        JME               AR            No candidates                                                                                                                                                                                                                                                              

JME: juvenile myoclonic epilepsy; EGTCS: epilepsy with generalized tonic-clonic seizures alone; AD: autosomal dominant; AR: autosomal recessive; Het: heterozygous; US: Uncertain significance.

### Family B {#sec019}

A 15-year-old girl (ID: LJY) presented with unprovoked GTCSs. She experienced unprovoked seizures since the age of 14 years that were characterized by brief episodes of myoclonic jerks, especially in the upper limbs, and GTCSs upon waking. A family history indicated epilepsy in her mother, who was diagnosed with JME. The mother was 40 years and had received treatment with an antiepileptic drug for approximately 3 years in her late teens and early twenties. The proband and her mother had no history of febrile convulsions. Given the autosomal dominant inheritance pattern and filtered heterozygous variants, no likely candidates were identified.

### Family C {#sec020}

A 17-year-old boy (ID: E-026-P) had a history of recurrent myoclonic jerks, predominantly upon awakening, and GTCSs that first appeared at 8 years of age. He was diagnosed with JME. His mother, dizygotic twin brother, and younger brother had similar clinical seizures, were also diagnosed with familial JME. There was no family history of febrile seizures. The proband's father was unaffected, and his DNA was obtained for control sequencing. Autosomal dominant inheritance from the mother was suspected; therefore, we filtered the variants. However, no candidate variants were identified.

### Family D {#sec021}

A 20-year-old man (ID: E-047-P) was confirmed to have JME. He first experienced myoclonic jerks and GTCSs upon waking at 8 years of age. His younger brother also developed similar seizures (myoclonic jerks and GTCSs) at 12 years of age, was also diagnosed with JME. Both patients did not have any history of febrile seizures. Considering the autosomal recessive inheritance pattern, homozygous variants were filtered; however, no candidate variants were identified. Although it did not fit the inheritance pattern, a rare heterozygous variant *JRK* p.(Ser388Leu) was observed in both affected family members. The characteristics of the *JRK* p.(Ser388Leu) variant are described in [S3 Table](#pone.0199321.s003){ref-type="supplementary-material"} and [Table 4](#pone.0199321.t004){ref-type="table"}. The proband also had the rare variant, *CACNA1A* p.(Ile239Phefs\*5), which was suspected as possibly pathogenic; however, his sibling did not have this variant [S2 Table](#pone.0199321.s002){ref-type="supplementary-material"} and [Table 4](#pone.0199321.t004){ref-type="table"}.

### Family E {#sec022}

A 19-year-old man (ID: E-087-P) was diagnosed with JME. He first experienced myoclonic jerks and GTCSs upon waking at 17 years of age. His younger brother was also diagnosed with JME, which developed at 12 years of age. Neither patient had a history of febrile seizures. He was treated with levetiracetam and his younger brother was treated with valproate. Considering the autosomal recessive inheritance pattern, homozygous variants were filtered; however, no candidate variants were identified. Although it did not fit the inheritance pattern, the rare heterozygous variant *GPR98* p.(Gly4447Asp), which is suspected of potentially causing the disease, was observed in both affected members. Characteristics of the *GPR98* p.(Gly4447Asp) are illustrated in [S3 Table](#pone.0199321.s003){ref-type="supplementary-material"} and [Table 4](#pone.0199321.t004){ref-type="table"}.

### Family F {#sec023}

A 23-year-old man (ID: E-184-P) was diagnosed with JME. He first experienced myoclonic jerks and GTCSs upon waking at 13 years old. His younger sister had similar seizures that developed at 10 years old. Neither had a history of febrile seizures. Considering the autosomal recessive inheritance pattern, we filtered homozygous variants and did not identify any candidates. Further, heterozygous rare variants or possible single variants were not detected.

Discussion {#sec024}
==========

Based on significant advances in our knowledge regarding the genetics of epileptogenic mechanisms in the recent decades, the present study was designed to test the hypothesis that known epilepsy genes, rather than unrecognized new genes, are responsible for common GGE syndromes. We aimed to conduct a focused analysis of potential candidate genes for common GGE syndromes using multi-gene panel testing with higher coverage depth and reduced burden of data analysis compared to WES. Analyses to determine pathogenic variants indicated very high genetic heterogeneity. Three pathogenic variants and 19 likely pathogenic variants on 16 different genes were identified. The diagnostic yield in common GGE syndromes was 28% (*n* = 16/57). Of the 22 candidate variants, 73% (*n* = 16/22) on 10 genes, including *GABRD*, *SCN1A*, *GRM4*, *CPA6*, *CHRNB3*, *CACNA1H*, *NDE1*, *CACNA1G*, *CACNA1A*, and *LGI4*, were sites for 50 candidate variants for common GGE syndromes. Interestingly, 27% of variants (*n* = 6/22) on 6 genes (*SZT2*, *DOCK7*, *GPR98*, *GATM*, *POLG*, and *ARX*) belonged to 61 causative genes known to be associated with other forms of genetic epilepsy. The results reinforced the hypothesis that common GGE syndromes are polygenic disorders with extreme locus and allelic heterogeneity.

Variants in voltage-gated Ca^2+^ channel genes including *CACNA1A*, *CACNA1G*, and *CACNA1H* were also frequently observed and accounted for 32% (*n* = 7/22) of the candidate variants. Voltage-sensitive calcium channels mediate the entry of Ca^2+^ into excitable cells and are also involved in a variety of Ca^2+^-dependent processes \[[@pone.0199321.ref014], [@pone.0199321.ref015]\]. Voltage-gated Ca^2+^ channel genes are known as susceptibility factors for GAE with typical absence seizures \[[@pone.0199321.ref015]\]. In the present study, pathogenic variants and likely pathogenic variants on *CACNA1A*, *CACNA1G*, and *CACNA1H* were found in 4 patients with JME and familial EGTCS, as shown in [Table 3](#pone.0199321.t003){ref-type="table"}. We suggested that voltage-gated Ca^2+^ channels are important to common GGE syndromes, as well as typical absence epilepsy.

*CACNA1H* variants (*n* = 4/22, 18%) were most frequently observed. The alpha-1H isoform produces T-type Ca^2+^ currents, and T-type Ca^2+^ channels belong to the low voltage-activated group. Particular characteristics of this type of channel include opening at highly negative potentials and voltage-dependent inactivation \[[@pone.0199321.ref014]\]. T-type channels serve pace-making functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscles \[[@pone.0199321.ref014]\]. They may also be involved in modulating neuronal firing patterns, which are crucial for information processing and cell growth processes \[[@pone.0199321.ref014]\]. *CACNA1H* activation produces T-type Ca^2+^ channels, and functional variations in *CACNA1H* are increased susceptibility to GGE \[[@pone.0199321.ref013], [@pone.0199321.ref016]\]. Previous studies have reported associations between common GGE syndromes and *CACNA1H*, especially GAE (CAE/JAE), primarily in the Chinese Han population \[[@pone.0199321.ref015], [@pone.0199321.ref017]--[@pone.0199321.ref019]\]. Eckle et al. \[[@pone.0199321.ref014]\] suggested that gain-of-function variants in *CACNA1H* directly increase seizure susceptibility by altering neuronal electrical properties, and indirectly increase seizure susceptibility by changing gene expression. Results of the present study suggest that *CACNA1H* c.2363G\>A p.(Arg788His) is a pathogenic variant responsible for autosomal dominant EGTCS in family A. This missense change occurred at an amino acid residue in which a *CACNA1H* c.2362C\>T (p.Arg816Cys) variant has been reported previously \[[@pone.0199321.ref013]\], and the p.Arg788Cys variant has been proposed as a functional polymorphism that occurs more frequently in people with IGEs than in the general population \[[@pone.0199321.ref013]\]. As such, the present study suggests that arginine 788 in *CACNA1H* is an important contributor to epilepsy.

Analyses to identify susceptibility variants using case-control association analyses indicated that 1 variant of *KCNMA1* c.400G\>C is significantly associated when the corrected *p* value was considered. The *KCNMA1* gene underlies Ca^2+^ activated K^+^ channels, which are fundamental to smooth muscle tone and neuronal excitability. Diseases associated with *KCNMA1* include autism, cerebellar atrophy, and generalized epilepsy and paroxysmal dyskinesia \[MIM 609446\]. Further, *KCNMA1* c.400G\>C may be the site of susceptibility variants in common GGE syndromes. However, results of the case-control association analyses are controversial, attributable to study limitations resulting from multi-gene panel testing and the relatively small sample size.

Although no meta-analysis study has been conducted, \<1% of common GGEs are suspected to be heritable Mendelian monogenic diseases \[[@pone.0199321.ref007]\]. In the present study, 6 patients had familial disease and underwent additional family segregation analyses. Of the 6 families, only 1 (family A) had the candidate variant p.(Arg788His) on the *CACNA1H* gene. The other 5 familial cases (B--F) did not exhibit any causative gene that was consistent with the inheritance pattern via linkage analysis. Interestingly, the present study did not find any variants that were consistent with expected Mendelian JME inheritance, such as variants of *CACNB4*, *CASR*, *GABRA1*, *GABRD*, *CLCN2*, or *EFHC1*. This unexpected result in familial analysis could have several causes. The possibility of monogenic disorders with variations in penetrance and expressivity of causative genes makes it difficult to identify the pathogenic variants. Despite high coverage and depth, challenges remain in the complete coverage of targeted regions, and it is impossible to identify copy number variations (CNVs) in multi-gene panel sequencing data. For recessive disorders such as those observed for families D--F, parental testing is particularly important for analyses of pathogenic variants. Unfortunately, we did not obtain parental DNA samples from families D--F. Each proband had several rare candidate variants; however, variants were not co-segregated in each family. In particular, family D and E exhibited *JRK* p.(Ser388Leu) and *GPR98* p.(Gly4447Asp), which are rare heterozygous candidate variants and were not consistent with the expected autosomal recessive inherited pattern. Recently, several genetic studies of familial GGE showed that no individual genes were significantly associated with familial GGE; however, several known epilepsy genes and variants were significantly enriched in a group of familial GGE \[[@pone.0199321.ref016], [@pone.0199321.ref020]\]. Therefore, familial cases may result from multi-genic disorders where interactions between multiple causative and susceptibility genes or variants with modest or strong effects produce sporadic cases.

In summary, we identified candidate genetic variants causing epilepsy susceptibility in about a quarter of the patients (28%, n = 16/57) in this study. An average of 2.8 variants was identified in each of the 57 patients. The results of this study reconfirm the polygenic disorder with very high locus/allelic heterogeneity of common GGE syndromes and suggest that voltage-gated Ca^2+^ channels are possibly important contributors to common GGE syndromes. Furthermore, these data suggest that common familial GGE syndromes are polygenic disorders with low penetrance and variable expressivity. Considering the possibility of ethnic and racial differences in the distribution of epilepsy susceptibility genes and an effect of genetic background on the epilepsy phenotype, it is worth noting that this study is the first analysis of a single ethnic group of Korean patients with common GGE syndromes using multi-gene panel testing. This study extends our comprehensive understanding of common GGEs.
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